title: Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
abstract: The majority of patients with a squamous cell carcinoma of the head and neck present with locally advanced tumors. The first-line treatment of locally advanced tumor stages consists of a combined modality management. Despite these aggressive protocols, many patients develop locoregional recurrences or metastasis and place particularly high demands on the interdisciplinary treatment team. Treatment with a curative intent must be differentiated from a palliative one. In addition to prior treatment, resectability, age and performance status, patient wishes must be taken into consideration in treatment planning, especially considering that most therapies offer little to no overall survival benefit. Salvage surgery, chemo- and target therapies, and reirradiation are head and neck surgeon's and radiooncologist's weapons in the fight against these strong opponents. This review focuses on publications and meeting news from last year and reviews the current status of the clinical application of each treatment modality in recurrent or metastatic head and neck cancer.
authors.affiliation: Department of Otolaryngology and Head and Neck Surgery, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. t.kurzweg@uke.uni-hamburg.de
authors.forename: T
authors.initials: T
authors.lastname: Kurzweg
authors.forename: N
authors.initials: N
authors.lastname: Möckelmann
authors.forename: S
authors.initials: S
authors.lastname: Laban
authors.forename: R
authors.initials: R
authors.lastname: Knecht
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D052117:Benzodioxoles / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D000068818:Cetuximab; D003131:Combined Modality Therapy; D000069439:Dasatinib; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005472:Fluorouracil / Q000627:therapeutic use; D000077156:Gefitinib; D006258:Head and Neck Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D010166:Palliative Care; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D052999:Quinazolinones / Q000627:therapeutic use; D016879:Salvage Therapy; D000077195:Squamous Cell Carcinoma of Head and Neck; D000077210:Sunitinib; D013844:Thiazoles / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D052117:Benzodioxoles; D007211:Indoles; D011743:Pyrimidines; D011758:Pyrroles; D011799:Quinazolines; D052999:Quinazolinones; D013844:Thiazoles; C525726:dacomitinib; C515233:saracatinib; D066246:ErbB Receptors; D000068818:Cetuximab; D000069439:Dasatinib; D000077156:Gefitinib; D005472:Fluorouracil; D000077210:Sunitinib